Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
immatics biotechnologies GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'immatics biotechnologies GmbH - Product Pipeline Review - 2014', provides an overview of the immatics biotechnologies GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of immatics biotechnologies GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of immatics biotechnologies GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of immatics biotechnologies GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the immatics biotechnologies GmbH's pipeline products Reasons to buy - Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of immatics biotechnologies GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of immatics biotechnologies GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 immatics biotechnologies GmbH Snapshot 4 immatics biotechnologies GmbH Overview 4 Key Information 4 Key Facts 4 immatics biotechnologies GmbH - Research and Development Overview 5 Key Therapeutic Areas 5 immatics biotechnologies GmbH - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Out-Licensed Products 9 Out-Licensed Products/Combination Treatment Modalities 10 immatics biotechnologies GmbH - Pipeline Products Glance 11 immatics biotechnologies GmbH - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 immatics biotechnologies GmbH - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 immatics biotechnologies GmbH - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 immatics biotechnologies GmbH - Drug Profiles 15 IMA-901 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 IMA-910 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 IMA-950 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 IMA-962 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 immatics biotechnologies GmbH - Pipeline Analysis 22 immatics biotechnologies GmbH - Pipeline Products by Route of Administration 22 immatics biotechnologies GmbH - Pipeline Products by Molecule Type 23 immatics biotechnologies GmbH - Recent Pipeline Updates 24 immatics biotechnologies GmbH - Company Statement 26 immatics biotechnologies GmbH - Locations And Subsidiaries 27 Head Office 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables immatics biotechnologies GmbH, Key Information 4 immatics biotechnologies GmbH, Key Facts 4 immatics biotechnologies GmbH - Pipeline by Indication, 2014 6 immatics biotechnologies GmbH - Pipeline by Stage of Development, 2014 7 immatics biotechnologies GmbH - Monotherapy Products in Pipeline, 2014 8 immatics biotechnologies GmbH - Out-Licensed Products in Pipeline, 2014 9 immatics biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014 10 immatics biotechnologies GmbH - Phase III, 2014 11 immatics biotechnologies GmbH - Phase II, 2014 12 immatics biotechnologies GmbH - Phase I, 2014 13 immatics biotechnologies GmbH - Preclinical, 2014 14 immatics biotechnologies GmbH - Pipeline by Route of Administration, 2014 22 immatics biotechnologies GmbH - Pipeline by Molecule Type, 2014 23 immatics biotechnologies GmbH - Recent Pipeline Updates, 2014 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.